睿昂基因(688217.SH):打造公司“設備+試劑+服務”的一體化優勢
格隆匯4月28日丨有投資者向睿昂基因(688217.SH)提問:請問公司如何看待血液腫瘤檢測的多種技術手段呢?
睿昂基因回覆:血液腫瘤檢測涉及到PCR、NGS、FISH、流式細胞免疫檢測多種技術手段。血液腫瘤檢測和實體腫瘤檢測不同,在實體腫瘤檢測中,通常NGS和PCR是一個二選一的關係,是互相競爭關係。而在血液腫瘤檢測領域,它的診斷是一個非常複雜的過程,通常是從細胞形態學、免疫學、細胞遺傳學、分子生物學等多維度,使用PCR、NGS、FISH、流式細胞免疫檢測來做一個綜合的判斷,這樣更有利於患者治療方案的確定。在三四線城市,由於基層醫院整體實力偏弱,往往不能為血液腫瘤患者提供上述多種的技術服務。公司希望加大在基層醫院的投入,打造公司“設備+試劑+服務”的一體化優勢,提高公司產品和服務在基層醫院的滲透率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.